Promomed Company participated in the Russian Bond Congress

On December 7-8, St. Petersburg hosted the XXI Russian Bond Congress, one of the largest business events in the field of financial markets, investment and debt securities markets.

The Russian Bond Congress annually gathers on its site the leading experts of the domestic stock market, representatives of financial organizations, state and municipal authorities. The participants summarize the results of the year and discuss the main trends in the development of the Russian investment market in the coming year. More information about the results of the Russian Bond Congress-2023 can be found at the link. This year, for the first time in history, the pharmaceutical company Promomed Group was invited to the Congress. It should be noted that Promomed Group is an experienced issuer – in 2020-2023, the company successfully placed four bond issues on the Moscow Stock Exchange.

Representatives of Promomed participated in a panel discussion, held a number of working meetings, and answered interested questions from analysts, investors, and Congress participants. Investors certainly showed interest in the experience of the Group's past placements, but they were more interested in what was happening in the domestic pharmaceutical market and the possibility of long-term investments in the development of the pharmaceutical industry.

Recognizing the experience and stable investment position of Promomed Group in the bond market, the organizers invited the Company to participate in the "Long-time Issuer" session.: how to always make successful releases." The speaker was Alexander Yefremov, CEO of Promomed Group, who described what factors shaped the company's success during past bond issues and why investments in Promomed will remain profitable and promising in the future. In his speech, Alexander Efremov confirmed the Group's strategy aimed at the production of innovative medicines and the introduction of high technologies in the treatment of complex diseases. This strategy is the basis of Promomed's work, it allows us to achieve high results, maintain and significantly increase the investment attractiveness of the Group. "For Promomed, success consists of several factors. Firstly, we offer innovative solutions in biopharmaceuticals, follow trends and, most importantly, shape trends in the industry. Promomed's new drugs and developments are aimed at treating diseases that were previously considered incurable. Our drugs make the basic therapy of a number of diseases safer, better and more effective. Secondly, Promomed Group has its own industrial enterprises where we synthesize almost any pharmaceutical substance and produce more than 250 drugs in 10 dosage forms. Thirdly, we work with fundamental science, so we have a vision of what treatment of socially significant diseases will look like in the near future. Promomed is already thinking about what doctors and patients will use as therapy tomorrow. All these factors allow us to be effective, show interesting financial results and make correct financial forecasts.

However, in addition to financial achievements, it is important for the Company to make its investors involved. Not only are financial forecasts and results always available to our investors, they see that there are millions of lives saved behind the numbers. That is why we work and will work together every day: we save lives together!" emphasized Alexander Yefremov.